Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NH102 Single Ascending Dose in Healthy Subjects
NCT05015192Phase 1Completed
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NH-102 in major depressive disorder (MDD) (6 arms), sponsored by Jiangsu Nhwa Pharmaceutical. Primary endpoint: Number of participants with adverse events. Started Aug 2021; status: completed.
02
Drugs
NH-102
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05015192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015192.